Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project

被引:15
作者
Low, Jeffrey [1 ]
Ross, Joseph S. [2 ,3 ,4 ,5 ]
Ritchie, Jessica D. [2 ]
Gross, Cary P. [3 ,4 ]
Lehman, Richard [6 ]
Lin, Haiqun [2 ,7 ]
Fu, Rongwei [8 ]
Stewart, Lesley A. [9 ]
Krumholz, Harlan M. [2 ,4 ,5 ,10 ]
机构
[1] Yale Sch Med, Dept Internal Med, 333 Cedar St, New Haven, CT 06510 USA
[2] Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, 1 Church St,Suite 200, New Haven, CT 06510 USA
[3] Yale Sch Med, Sect Gen Internal Med, Dept Internal Med, POB 208093, New Haven, CT 06510 USA
[4] Robert Wood Johnson Fdn, Clin Scholars Program, POB 208088, New Haven, CT 06510 USA
[5] Yale Sch Publ Hlth, Dept Hlth Policy & Management, POB 208034, New Haven, CT 06520 USA
[6] Univ Oxford, Dept Primary Care Hlth Sci, 33 St Ebbes St, Oxford OX1 1PU, England
[7] Yale Sch Publ Hlth, Dept Biostat, POB 208034, New Haven, CT 06520 USA
[8] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Pacific Northwest Evidence Based Practice Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA
[9] Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England
[10] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, POB 208093, New Haven, CT 06510 USA
关键词
Data sharing; Data interpretation; Systematic review; Meta-analysis; INDIVIDUAL PATIENT DATA; SPINAL-FUSION; LEVEL DATA; METAANALYSIS; COMPLICATIONS; SAFETY;
D O I
10.1186/s13643-017-0422-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It is uncertain whether the replication of systematic reviews, particularly those with the same objectives and resources, would employ similar methods and/or arrive at identical findings. We compared the results and conclusions of two concurrent systematic reviews undertaken by two independent research teams provided with the same objectives, resources, and individual participant-level data. Methods: Two centers in the USA and UK were each provided with participant-level data on 17 multi-site clinical trials of recombinant human bone morphogenetic protein-2 (rhBMP-2). The teams were blinded to each other's methods and findings until after publication. We conducted a retrospective structured comparison of the results of the two systematic reviews. The main outcome measures included (1) trial inclusion criteria; (2) statistical methods; (3) summary efficacy and risk estimates; and (4) conclusions. Results: The two research teams' meta-analyses inclusion criteria were broadly similar but differed slightly in trial inclusion and research methodology. They obtained similar results in summary estimates of most clinical outcomes and adverse events. Center A incorporated all trials into summary estimates of efficacy and harms, while Center B concentrated on analyses stratified by surgical approach. Center A found a statistically significant, but small, benefit whereas Center B reported no advantage. In the analysis of harms, neither showed an increased cancer risk at 48 months, although Center B reported a significant increase at 24 months. Conclusions reflected these differences in summary estimates of benefit balanced with small but potentially important risk of harm. Conclusions: Two independent groups given the same research objectives, data, resources, funding, and time produced broad general agreement but differed in several areas. These differences, the importance of which is debatable, indicate the value of the availability of data to allow for more than a single approach and a single interpretation of the data.
引用
收藏
页数:9
相关论文
共 32 条
  • [1] [Anonymous], 1997, LANCET, V350, P675
  • [2] [Anonymous], AM J REPROD IMMUNOL
  • [3] AOKI K, 1994, AM J REPROD IMMUNOL, V32, P55
  • [4] Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head
    Berlin, JA
    Santanna, J
    Schmid, CH
    Szczech, LA
    Feldman, HI
    [J]. STATISTICS IN MEDICINE, 2002, 21 (03) : 371 - 387
  • [5] Prevalence, Complications, and Hospital Charges Associated With Use of Bone-Morphogenetic Proteins in Spinal Fusion Procedures
    Cahill, Kevin S.
    Chi, John H.
    Day, Arthur
    Claus, Elizabeth B.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (01): : 58 - 66
  • [6] A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned
    Carragee, Eugene J.
    Hurwitz, Eric L.
    Weiner, Bradley K.
    [J]. SPINE JOURNAL, 2011, 11 (06) : 471 - 491
  • [7] Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Spine Fusion A Systematic Review and Meta-analysis
    Fu, Rongwei
    Selph, Shelley
    McDonagh, Marian
    Peterson, Kimberly
    Tiwari, Arpita
    Chou, Roger
    Helfand, Mark
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 158 (12) : 890 - +
  • [8] Waste recombinant DNA: Effectiveness of thermo-treatment to manage potential gene pollution
    Fu, Xiaohua
    Li, Mengnan
    Zheng, Guanghong
    Le, Yiquan
    Wang, Lei
    [J]. ENVIRONMENTAL POLLUTION, 2009, 157 (8-9) : 2536 - 2541
  • [9] RhBMP-2 Versus Iliac Crest Bone Graft for Lumbar Spine Fusion
    Glassman, Steven D.
    Carreon, Leah Y.
    Djurasovic, Mladen
    Campbell, Mitchell J.
    Puno, Rolando M.
    Johnson, John R.
    Dimar, John R.
    [J]. SPINE, 2008, 33 (26) : 2843 - 2849
  • [10] Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
    Hart, Beth
    Lundh, Andreas
    Bero, Lisa
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 344